We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
- Authors
Raut, Chandrajit P; Boucher, Yves; Duda, Dan G; Morgan, Jeffrey A; Quek, Richard; Ancukiewicz, Marek; Lahdenranta, Johanna; Eder, J Paul; Demetri, George D; Jain, Rakesh K
- Abstract
Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density.
- Publication
PloS one, 2012, Vol 7, Issue 2, pe26331
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0026331